In metastatic prostate cancer and advanced melanoma patients, ipilimumab treatment induced a significant increase in Ag-specific humoral and CTL responses, while levels of suppressive FoxP3+ Tregs remained stable or were expanded [66,139,141]. Here, FOXP3 is linked to metastatic prostate carcinoma.